# Krishna Institute of Medical Sciences share price today (Krishna Institute of Medical Sciences Ltd, NSE: KIMS)

> Krishna Institute of Medical Sciences share price today: ₹740.55 at the NSE close on 4 November 2026, up 1.7% in a year. Krishna Institute of Medical Sciences (NSE: KIMS) is worth ₹31,095 crore, trades at a P/E of 148.7 and has closed between ₹582.10 and ₹850.65 over the past 52 weeks. > Krishna Institute of Medical Sciences Ltd's share price has risen faster than its earnings: +1.7% in a year, against −37.3% for earnings per share. KIMS · Hospitals · data as of 4 November 2026. Page: https://www.sectoralpha.in/stocks/krishna-institute-of-medical-sciences-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Getting worse, from fewer quarters than usual
- Price: ₹740.55 (+1.7% in a year)
- P/E: 148.7× (higher than 97% of the last 5.3 years)
- Revenue (Jun 2026): ₹1,180 Cr (+35.3% on a year ago)
- Profit (Jun 2026): ₹37.0 Cr (−56.5% on a year ago)
- Operating margin: 19.0% (−3.0 points on a year ago)
- ROCE: 10%, FY26
- Profit that came in as cash: 163%, last 3 years

The main question: the share price moved +1.7% in a year while yearly earnings per share moved −37.3%. The difference came from the market paying a higher multiple. ## What is the Krishna Institute of Medical Sciences share price today? Krishna Institute of Medical Sciences Ltd's share price was ₹740.55 at the close on 4 November 2026. It has been rising for 25 weeks. That is 1.1% above its average price over the last 200 trading days. Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 7 weeks running. In the last 52 weeks it traded between ₹582 and ₹851, and at that close it sat 59% of the way up from that low. Over the last 5.3 years the share price moved +264% while the NIFTY 500 moved +61%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 18 September 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Krishna Institute of Medical Sciences this quarter? 1. Revenue up on a year earlier for 11 quarters in a row (every quarter we can compare) In the June 2026 quarter revenue was ₹1,180 crore, +35.3% on a year earlier. Why: Revenue rose because more patients came to its hospitals. Inpatient visits and outpatient visits both grew from a year earlier. Next results: check whether the new insurance approvals bring more patients to the new hospitals. From the earnings call on 4 Aug 2026. 3. Foreign funds (FIIs) raised their stake for 3 quarters in a row From 14.3% to 15% of the company by the September 2026 quarter. ## What are Krishna Institute of Medical Sciences' latest quarterly results? For April to June 2026 (the quarter ended 30 June 2026), Krishna Institute of Medical Sciences reported revenue of ₹1,180 crore, up 35.3% from ₹872 crore a year earlier, and a profit of ₹37.0 crore, down 56.5% from ₹85.0 crore. ### Krishna Institute of Medical Sciences results: April to June 2026 against a year earlier

| Measure | April to June 2026 | April to June 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹1,180 crore | ₹872 crore | +35.3% |
| Profit | ₹37.0 crore | ₹85.0 crore | −56.5% |
| Earnings per share | ₹0.99 | ₹1.96 | −49.5% |
| Operating margin | 19.0% | 22.0% | −3.0 points |

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). Krishna Institute of Medical Sciences' management discussed these results on a call held on 4 August 2026; what it said is further down this page. (From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.)

## What is the Krishna Institute of Medical Sciences share price history? Krishna Institute of Medical Sciences closed at ₹740.55 on 4 November 2026, up 1.7% from ₹728.10 a year earlier (7 November 2025) and up 219.1% over five years. Its highest weekly close since July 2021 was ₹850.65 on 3 July 2026. ### Krishna Institute of Medical Sciences share price: then and now

| When | Close | Change to 4 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 30 Oct 2026 | ₹701.80 | +5.5% |
| 1 month ago · 1 Oct 2026 | ₹736.25 | +0.6% |
| 6 months ago · 8 May 2026 | ₹717.60 | +3.2% |
| 1 year ago · 7 Nov 2025 | ₹728.10 | +1.7% |
| 3 years ago · 3 Nov 2023 | ₹372.04 | +99.1% |
| 5 years ago · 4 Nov 2021 | ₹232.05 | +219.1% |
| Earliest and lowest weekly close in our records · 2 Jul 2021 | ₹203.65 | +263.6% |
| Highest weekly close since July 2021, also the 52-week high · 3 Jul 2026 | ₹850.65 | −12.9% |
| 52-week low (weekly close) · 23 Jan 2026 | ₹582.10 | +27.2% |

Weekly closing prices, adjusted for splits and bonuses so every price is on today’s share count. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (286 weekly closes from 2 July 2021 to 4 November 2026.)

## What is the latest news on Krishna Institute of Medical Sciences? 4 Nov 2026: Krishna Institute of Medical Sciences closed at ₹740.55, up 5.5% on the week and up 0.6% on the month. 4 Aug 2026: Krishna Institute of Medical Sciences held its results call for April to June 2026. Management guided: Current hospitals prioritized for stabilization over the next two quarters; Nashik commissioning planned in three to four months, Electronic City break-even within one to two quarters, and Bangalore full-year operating profit neutrality. ### Earlier

- Results for April to June 2026: Revenue up 35.3% and profit down 56.5% on a year earlier. - 13 Sep 2024: Share split: face value cut from ₹10 to ₹2 a share (ex-date). ## What dividend does Krishna Institute of Medical Sciences pay? Krishna Institute of Medical Sciences has paid no dividend on the NSE since its first NSE close in our records (2 July 2021), the start of the period we checked. No. Krishna Institute of Medical Sciences Ltd paid out 0% of its profit as dividends in each of its last 11 reported years, so there is no payout history to show. That comes from the filed annual statements, not an estimate. (From the NSE corporate-actions record, read 5 November 2026.)

## What did Krishna Institute of Medical Sciences management say on the latest results call? On the call for April to June 2026, held on 4 August 2026, Krishna Institute of Medical Sciences' management guided: Current hospitals prioritized for stabilization over the next two quarters; Nashik commissioning planned in three to four months, Electronic City break-even within one to two quarters, and Bangalore full-year operating profit neutrality. > “We are not looking at opening any new geography.”
> Dr. Abhinay Bollineni, on the call for April to June 2026

### What management guided

- Key insurer empanelments for Nashik, Thane and both Bangalore assets planned by end-August or mid-September, with the majority complete by year-end; Bangalore ARPOB to settle around ₹82,000-85,000 after empanelment. - Kerala operating margin to remain single-digit through FY27, move to mid-teens next year, and stabilize around 20-22% over the following two to three years. - Kondapur revenue potential around ₹100 crore monthly or ₹1,200 crore annually over four to five years; modelled margin 30-32% at scale. - ARPOB growth of 4-5% is a reasonable ongoing assumption; current hospitals to reach 65-70% occupancy by FY30 without additional beds, with Telangana operating margin returning to 30-35% as capacity matures. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijorifinance.com/insight/india/43300/Conference Call/CC-Aug26.pdf). (From the call for April to June 2026, 4 August 2026.)

## What to watch in Krishna Institute of Medical Sciences' next results? When Krishna Institute of Medical Sciences reports July to September 2026, these are the 4 checks that show whether the story is still on course. First: Electronic City and the Bangalore cluster: check whether the remaining drag narrows as monthly break-even converts into reported-quarter progress. - What to check (from the call)
- Electronic City and the Bangalore cluster: check whether the remaining drag narrows as monthly break-even converts into reported-quarter progress. - Nashik, Thane and Bangalore insurer empanelments: check whether the promised near-term completions unlock new-unit volume and revenue acceleration. - Next-quarter interest expense after QIP repayment: check whether the late-quarter debt reduction flows through as management indicated. - Kondapur ramp and old-facility exit: check whether early growth offsets legacy rental and operating costs before the transition decision. ## Which stock lists is Krishna Institute of Medical Sciences on? Krishna Institute of Medical Sciences is on one of our India lists: Small & mid cap stocks. [Small & mid cap stocks Size rank in India: 275](https://www.sectoralpha.in/small-cap-stocks-india)

## Is Krishna Institute of Medical Sciences profitable? Krishna Institute of Medical Sciences Ltd earned ₹37.0 Cr of net profit in the Jun 2026 quarter, −56.5% on the same quarter a year earlier. Full-year FY26 profit was ₹242 Cr. Over 10 years profit has grown 24.1% a year on average. That is 3.1% of the quarter's revenue. The same quarter a year earlier earned ₹85.0 Cr. For the full year, FY26 profit was ₹242 Cr (−41.7% on the year before). Why profit moved: revenue changed +35.3% on a year earlier and the margin moved −3.0 percentage points. Sales did the work while the margin got thinner. On average over the last four quarters, profit changed −52.4% and revenue +30.8%. Profit is growing slower than sales: rising costs are taking part of the growth. ## How much revenue does Krishna Institute of Medical Sciences make, and is it growing? Krishna Institute of Medical Sciences Ltd reported ₹1,180 Cr of revenue in the Jun 2026 quarter, +35.3% on the same quarter a year earlier. That is the 11th quarter in a row with growth on the year before. Over 10 years it has grown 22.5% a year on average. The last full year, FY26, came in at ₹3,905 Cr. The last four reported quarters add to ₹4,214 Cr. FY26 revenue was ₹3,905 Cr, +28.7% on the year before. Recent pace: the last four quarters grew +30.8% on average, against 22.5% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +31.0%, against +27.8% a year over the last 8 quarters (accelerating); profit over the last 12 months grew −52.0%, against −25.0% a year (rolling over). ## How much of every ₹100 of sales does Krishna Institute of Medical Sciences keep? Krishna Institute of Medical Sciences Ltd's operating margin was 19.0% in the Jun 2026 quarter, 3.0 percentage points lower than the same quarter a year ago. Across 11 years it has been between 9.0% and 32.0%. The latest quarter is within that range. Why the margin moved: operating margin changed −3.2 percentage points on the year while gross margin changed +0.4 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Krishna Institute of Medical Sciences' profit turning into cash? Over the last 3 years, 163% of Krishna Institute of Medical Sciences Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹511 Cr of operating cash against ₹242 Cr of profit. After ₹2,037 Cr of spending on assets, free cash was −₹1,526 Cr: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 163% of profit came in as cash: the cash cycle got 158 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. What to look at next: the bigger use of cash is spending on new assets, at 7.7× depreciation over three years. The next section checks what that spending is building. ## Where does Krishna Institute of Medical Sciences' cash go? Krishna Institute of Medical Sciences Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 52 days in FY26, up from −106 days in FY21. It spent ₹4,680 Cr on assets over the last 3 years. Customers take 52 days to pay, and stock sits for 44 days on average. At FY26 sales of ₹3,905 Cr, each day of that cycle ties up about ₹10.7 Cr, so roughly ₹556 Cr is tied up in the business at any time. FY26: customers took 52 days to pay and stock sat for 44 days, about 1.4 months of sales sitting as stock, for a full cycle of 52 days, longer than FY21's −106. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 44 days. Customers pay about 52 days after that. Suppliers are paid at 146 days. Together that makes the 52-day cycle. Spending on assets: ₹4,680 Cr over the last 3 years, against ₹607 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹606 Cr (FY26): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Krishna Institute of Medical Sciences' P/E ratio, and how does it compare with its own history? Krishna Institute of Medical Sciences Ltd's P/E is 148.7×, near the high end of its own history: higher than 97% of past readings. Its usual P/E (the middle reading) is 52.7×, over 5.3 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Jun 2026 add up to ₹5.05. Why the multiple is where it is: over the past year earnings per share moved −37.3% while the price moved +1.7%. The price did better than earnings, which pushed the multiple up within its own range. Where the price move came from: over 5 years the price moved +26.1% a year; about −0.3% a year came from earnings growth and about +26.4 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple. The PEG ratio and its quarterly curve, which only the second data source has, are not shown on this page: its two data sources disagree by up to 27% on reported income across 15 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## Is the Krishna Institute of Medical Sciences business getting better or worse? Krishna Institute of Medical Sciences Ltd's business is getting worse. Profit and EPS growth are shrinking: profit growth is −52.0% in the latest quarter, against +22.8% at its best in 12 quarters, with ROCE falling at 10.0%. This is based on 8 quarters of 4 measures, with some gaps. Why it matters: falling lines mean any ratio below that looks low should be read with that direction in mind. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. This reading has some gaps: at least one line is short, or the return line is not the quarterly series, so treat it with a little more caution. ## What is Krishna Institute of Medical Sciences management's track record? October to December 2025 revenue crossed ₹1,000 Cr milestone (+26.9% on a year earlier), operating profit ₹204 Cr (20.4% margin), ARPOB +20.5% on a year earlier. BUT profit collapsed -39.9% on a year earlier to ₹52 Cr due to new hospital drag. New 350-bed Bangalore Electronic City hospital started Dec 2025, breakeven 12+ months away. ### Regulatory and governance record

No fraud or controversies. Promoter pledge activity (Jun 2024, ~₹330 Cr) partially revoked by Sep 2024. Not a structural concern but flagged. (Checked 22 March 2026.)

## How much does Krishna Institute of Medical Sciences earn on its capital? Krishna Institute of Medical Sciences Ltd earned a ROCE of 10% in FY26. That is up from a low of 5% in FY19. We cannot compare its return on capital used with its cost of capital from the data we have. It comes from a 6.2% net margin and 0.51× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 6.2% net margin × 0.51× asset turnover × 3.42× leverage (assets divided by equity) ≈ 10.8% on equity. The margin does its share; borrowing is a big part of it. The quarterly return lines and the return-on-capital-used (ROIC) line, which only the second data source has, are not shown on this page: its two data sources disagree by up to 27% on reported income across 15 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## Does Krishna Institute of Medical Sciences have too much debt? Krishna Institute of Medical Sciences Ltd had ₹4,253 Cr of borrowings against ₹2,247 Cr of equity in FY26, so its debt is 1.89× its equity. Its operating profit is 4 times its interest bill. Over 5 years borrowings went from ₹316 Cr to ₹4,253 Cr. Over the last 3 of those years it spent ₹4,680 Cr on assets. Part of the spending on assets is being paid for with borrowed money. The total-debt and debt-to-equity series, which only the second data source has, are not shown on this page: its two data sources disagree by up to 27% on reported income across 15 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## What is the Krishna Institute of Medical Sciences shareholding pattern? Promoters cut their stake in Krishna Institute of Medical Sciences Ltd by 6.2 percentage points over 8 quarters, the biggest change among its owners. Promoters now own 32.6% of the company. Domestic institutions moved +0.9 points over the same period, to 33.2%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Promoters: −6.2 points over 8 quarters, to 32.6%; Domestic institutions: +0.9 points over 8 quarters, to 33.2%; Foreign institutions: −0.8 points over 8 quarters, to 15.0%. Why the owners changed: promoters drove it (−6.2 points), with the other side taken by domestic institutions (+0.9 points). They reduced their stake. ## How far is Krishna Institute of Medical Sciences from balance-sheet trouble? For Krishna Institute of Medical Sciences Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Krishna Institute of Medical Sciences rank in its industry? 34.8 out of 100, rank 17 of 20 in Hospitals, with 78% of the evidence available. Krishna Institute of Medical Sciences Ltd scores 34.8 out of 100 against the 20 companies it is compared with in Hospitals, ranking 17. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 10.3 + 9.1 + 6.1 + 9.3 = 34.8. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Krishna Institute of Medical Sciences compared with? Krishna Institute of Medical Sciences ranks 17 of 20 Hospitals companies on the 4-Factor Sector Score, with 34.8 out of 100. 1. [KMC Speciality Hospitals (India) Ltd](https://www.sectoralpha.in/stocks/kmc-speciality-hospitals-indialtd) KMCSHIL · breaking out · Sector-leading setup · 81% evidence 80.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.0/35 · Revenue 35.1% · Profit 100% · Operating margin change 6 points · 88% evidence Capital efficiency 23.0/25 · ROCE 26.2% · Operating margin 31% · 100% evidence Valuation 14.1/20 · P/E 43.4× · PEG 0.68 · 100% evidence Relative strength 12.5/20 · Lead over its industry n/a · Lead over NIFTY 500 45.6% · 1 year 115.4% · 25% evidence · 5 of 5 weeks ahead Exact sum: 31 + 23 + 14.1 + 12.5 = 80.6 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Sakar Healthcare Ltd](https://www.sectoralpha.in/stocks/sakar-healthcare-ltd) SAKAR · leader · Most evidence points up · 100% evidence 68.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 32.5/35 · Revenue 47.5% · Profit 100% · Operating margin change 8 points · 100% evidence Capital efficiency 11.4/25 · ROCE 12.4% · Operating margin 28% · 100% evidence Valuation 11.1/20 · P/E 49× · PEG 1.05 · 100% evidence Relative strength 13.8/20 · Lead over its industry 41.8% · Lead over NIFTY 500 45.4% · 1 year 161.6% · 100% evidence · 12 of 12 weeks ahead Exact sum: 32.5 + 11.4 + 11.1 + 13.8 = 68.8 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. [Apollo Hospitals Enterprise Ltd](https://www.sectoralpha.in/stocks/apollo-hospitals-enterprise-ltd) APOLLOHOSP · turning · Most evidence points up · 78% evidence 68.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.0/35 · Revenue 17.2% · Profit 33.2% · Operating margin change 1 points · 83% evidence Capital efficiency 15.2/25 · ROCE 17.4% · Operating margin 16% · 76% evidence Valuation 12.7/20 · P/E 57.7× · PEG n/a · 50% evidence Relative strength 16.6/20 · Lead over its industry 6.6% · Lead over NIFTY 500 11.2% · 1 year 10% · 100% evidence · 4 of 12 weeks ahead Exact sum: 24 + 15.2 + 12.7 + 16.6 = 68.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Dr Agarwals Eye Hospital Ltd](https://www.sectoralpha.in/stocks/dr-agarwals-eye-hospital-ltd) DRAGARWQ · breaking out · Evidence leans up · 81% evidence 62.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.1/35 · Revenue 20.1% · Profit 31.6% · Operating margin change -2 points · 88% evidence Capital efficiency 17.3/25 · ROCE 17.2% · Operating margin 30% · 100% evidence Valuation 12.5/20 · P/E 33.7× · PEG 1.36 · 100% evidence Relative strength 11.6/20 · Lead over its industry n/a · Lead over NIFTY 500 9.2% · 1 year 0.8% · 25% evidence · 8 of 12 weeks ahead Exact sum: 21.1 + 17.3 + 12.5 + 11.6 = 62.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Kovai Medical Center & Hospital Ltd](https://www.sectoralpha.in/stocks/kovai-medical-center-hospital-ltd) KOVAI · breaking out · Evidence leans up · 96% evidence 61.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 18.8/35 · Revenue 15% · Profit 15.8% · Operating margin change 1 points · 88% evidence Capital efficiency 19.1/25 · ROCE 22.6% · Operating margin 29% · 100% evidence Valuation 8.9/20 · P/E 24.8× · PEG 2.01 · 100% evidence Relative strength 14.7/20 · Lead over its industry 1.9% · Lead over NIFTY 500 6.6% · 1 year -9.2% · 100% evidence · 10 of 12 weeks ahead Exact sum: 18.8 + 19.1 + 8.9 + 14.7 = 61.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [GPT Healthcare Ltd](https://www.sectoralpha.in/stocks/gpt-healthcare-ltd) GPTHEALTH · quiet · Evidence leans up · 81% evidence 61.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 15.4/35 · Revenue 18% · Profit 0% · Operating margin change 3 points · 88% evidence Capital efficiency 18.1/25 · ROCE 19.9% · Operating margin 19% · 100% evidence Valuation 18.5/20 · P/E 23× · PEG 0.94 · 100% evidence Relative strength 9.1/20 · Lead over its industry n/a · Lead over NIFTY 500 -2.1% · 1 year -10.7% · 25% evidence · 4 of 12 weeks ahead Exact sum: 15.4 + 18.1 + 18.5 + 9.1 = 61.1 · What this means: The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far. 7. [Yatharth Hospital & Trauma Care Services Ltd](https://www.sectoralpha.in/stocks/yatharth-hospital-trauma-care-services-ltd) YATHARTH · breaking out · Evidence leans up · 78% evidence 57.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.4/35 · Revenue 43.9% · Profit 22.5% · Operating margin change -2 points · 83% evidence Capital efficiency 12.4/25 · ROCE 12.9% · Operating margin 23% · 76% evidence Valuation 6.7/20 · P/E 49.3× · PEG n/a · 50% evidence Relative strength 19.1/20 · Lead over its industry 17.1% · Lead over NIFTY 500 21.6% · 1 year 16.4% · 100% evidence · 10 of 12 weeks ahead Exact sum: 19.4 + 12.4 + 6.7 + 19.1 = 57.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Artemis Medicare Services Ltd](https://www.sectoralpha.in/stocks/artemis-medicare-services-ltd) ARTEMISMED · leader · Evidence leans up · 100% evidence 56.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.4/35 · Revenue 14.7% · Profit 20% · Operating margin change 0 points · 100% evidence Capital efficiency 12.7/25 · ROCE 14.6% · Operating margin 18% · 100% evidence Valuation 8.0/20 · P/E 39.7× · PEG 2.44 · 100% evidence Relative strength 16.7/20 · Lead over its industry 8.4% · Lead over NIFTY 500 12.9% · 1 year 18.4% · 100% evidence · 12 of 12 weeks ahead Exact sum: 19.4 + 12.7 + 8 + 16.7 = 56.8 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. [Global Health Ltd](https://www.sectoralpha.in/stocks/global-health-ltd) MEDANTA · losing its lead · Evidence leans up · 96% evidence 52.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 13.5/35 · Revenue 21.3% · Profit 3.4% · Operating margin change -2 points · 88% evidence Capital efficiency 18.8/25 · ROCE 17.4% · Operating margin 22% · 100% evidence Valuation 5.5/20 · P/E 59.7× · PEG 9.11 · 100% evidence Relative strength 14.2/20 · Lead over its industry 3.7% · Lead over NIFTY 500 8.1% · 1 year -3.1% · 100% evidence · 8 of 12 weeks ahead Exact sum: 13.5 + 18.8 + 5.5 + 14.2 = 52 · What this means: Relative strength against the index is 8.1%, and revenue and profit growth are weak. 10. [Indraprastha Medical Corporation Ltd](https://www.sectoralpha.in/stocks/indraprastha-medical-corporation-ltd) INDRAMEDCO · quiet · Evidence leans up · 85% evidence 51.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 13.3/35 · Revenue 10.8% · Profit 10.9% · Operating margin change 0 points · 100% evidence Capital efficiency 17.6/25 · ROCE 35.8% · Operating margin 19% · 100% evidence Valuation 13.2/20 · P/E 14.6× · PEG 1.47 · 100% evidence Relative strength 7.7/20 · Lead over its industry n/a · Lead over NIFTY 500 -19.7% · 1 year -49.6% · 25% evidence · 0 of 12 weeks ahead Exact sum: 13.3 + 17.6 + 13.2 + 7.7 = 51.8 · What this means: The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far. 11. [Rainbow Childrens Medicare Ltd](https://www.sectoralpha.in/stocks/rainbow-childrens-medicare-ltd) RAINBOW · quiet · Evidence leans up · 100% evidence 50.1 out of 100 Growth Capital Valuation Relative
12. [Max Healthcare Institute Ltd](https://www.sectoralpha.in/stocks/max-healthcare-institute-ltd) MAXHEALTH · quiet · Evidence leans down · 85% evidence 48.5 out of 100 Growth Capital Valuation Relative
13. [Fortis Healthcare Ltd](https://www.sectoralpha.in/stocks/fortis-healthcare-ltd) FORTIS · basing · Evidence leans down · 78% evidence 45.1 out of 100 Growth Capital Valuation Relative
14. [Shalby Ltd](https://www.sectoralpha.in/stocks/shalby-ltd) SHALBY · quiet · Evidence leans down · 63% evidence 42.0 out of 100 Growth Capital Valuation Relative
15. [Narayana Hrudayalaya Ltd](https://www.sectoralpha.in/stocks/narayana-hrudayalaya-ltd) NH · quiet · Evidence leans down · 78% evidence 40.7 out of 100 Growth Capital Valuation Relative
16. [Aster DM Quality Care Ltd](https://www.sectoralpha.in/stocks/aster-dm-quality-care-ltd) ASTERDM · quiet · Evidence leans down · 96% evidence 35.0 out of 100 Growth Capital Valuation Relative
17. Krishna Institute of Medical Sciences Ltd this page KIMS · quiet · Most evidence points down · 78% evidence 34.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 10.3/35 · Revenue 30.9% · Profit -52% · Operating margin change -3 points · 83% evidence Capital efficiency 9.1/25 · ROCE 9.5% · Operating margin 19% · 76% evidence Valuation 6.1/20 · P/E 141× · PEG n/a · 50% evidence Relative strength 9.3/20 · Lead over its industry -1.2% · Lead over NIFTY 500 3.1% · 1 year -2.7% · 100% evidence · 0 of 12 weeks ahead Exact sum: 10.3 + 9.1 + 6.1 + 9.3 = 34.8 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 18. [Jupiter Life Line Hospitals Ltd](https://www.sectoralpha.in/stocks/jupiter-life-line-hospitals-ltd) JLHL · quiet · Most evidence points down · 100% evidence 33.0 out of 100 Growth Capital Valuation Relative
19. [Healthcare Global Enterprises Ltd](https://www.sectoralpha.in/stocks/healthcare-global-enterprises-ltd) HCG · quiet · Most evidence points down · 71% evidence 31.1 out of 100 Growth Capital Valuation Relative
20. [Manipal Health Enterprises Ltd](https://www.sectoralpha.in/stocks/manipal-health-enterprises-ltd) MANIPALHOS · Too little evidence to rank firmly · 38% evidence 42.4 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Hospitals](https://www.sectoralpha.in/sectors/hospitals), all 20 compared on one page. ## Which companies are close to Krishna Institute of Medical Sciences in size? Krishna Institute of Medical Sciences is the 8th largest of 20 Hospitals companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Fortis Healthcare, Narayana Hrudayalaya and Global Health. Just below it: Rainbow Childrens Medicare, Yatharth Hospital & Trauma Care Services and Healthcare Global Enterprises. ### Hospitals companies close in size

1. [Fortis Healthcare Ltd](https://www.sectoralpha.in/stocks/fortis-healthcare-ltd) ₹57,992 crore
2. [Narayana Hrudayalaya Ltd](https://www.sectoralpha.in/stocks/narayana-hrudayalaya-ltd) ₹35,154 crore
3. [Global Health Ltd](https://www.sectoralpha.in/stocks/global-health-ltd) ₹34,156 crore
4. Krishna Institute of Medical Sciences Ltd ₹29,476 crore
5. [Rainbow Childrens Medicare Ltd](https://www.sectoralpha.in/stocks/rainbow-childrens-medicare-ltd) ₹12,378 crore
6. [Yatharth Hospital & Trauma Care Services Ltd](https://www.sectoralpha.in/stocks/yatharth-hospital-trauma-care-services-ltd) ₹8,931 crore
7. [Healthcare Global Enterprises Ltd](https://www.sectoralpha.in/stocks/healthcare-global-enterprises-ltd) ₹8,742 crore

[All 20 Hospitals companies, largest first](https://www.sectoralpha.in/sectors/hospitals#all-companies)

### Companies close in size in other industries

1. [Godrej Industries Ltd](https://www.sectoralpha.in/stocks/godrej-industries-ltd) ₹30,482 crore · Finance - Holding Company
2. [Mangalore Refinery And Petrochemicals Ltd](https://www.sectoralpha.in/stocks/mangalore-refinery-and-petrochemicals-ltd) ₹30,346 crore · Refineries
3. Krishna Institute of Medical Sciences Ltd ₹29,476 crore
4. [Cochin Shipyard Ltd](https://www.sectoralpha.in/stocks/cochin-shipyard-ltd) ₹29,312 crore · Ship - Docks/Breaking/Repairs
5. [Inventurus Knowledge Solutions Ltd](https://www.sectoralpha.in/stocks/inventurus-knowledge-solutions-ltd) ₹29,248 crore · IT Enabled Services/Business Process Outsourcing

## What else do people ask about Krishna Institute of Medical Sciences? ### What is Krishna Institute of Medical Sciences's share price today? Krishna Institute of Medical Sciences Ltd's share price is ₹740.55, +1.7% over the past year. The whole company is worth ₹31,095 Cr on the market. In the last 52 weeks it traded between ₹582 to ₹851; today it is 59% of the way up from the low, 1.1% above its 200-day average (as of 4 November 2026). ### What were Krishna Institute of Medical Sciences's latest quarterly results? Krishna Institute of Medical Sciences Ltd reported revenue of ₹1,180 Cr and net profit of ₹37.0 Cr for the Jun 2026 quarter. Revenue rose 35.3% and profit fell 56.5% compared with a year earlier. Earnings per share were ₹0.99 (as of 4 November 2026). ### What is Krishna Institute of Medical Sciences's market cap? Krishna Institute of Medical Sciences Ltd's market capitalisation is ₹31,095 Cr at a share price of ₹740.55. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 4 November 2026). ### How is Krishna Institute of Medical Sciences performing? Krishna Institute of Medical Sciences Ltd's share price has been rising for 25 weeks. In its latest quarter, revenue rose 35.3% and profit fell 56.5% compared with a year earlier. Over the past 13 weeks it has done worse than the NIFTY 500, for 7 weeks running (as of 4 November 2026). ### Will Krishna Institute of Medical Sciences's share price go up? This page does not forecast Krishna Institute of Medical Sciences Ltd's share price. What it shows instead: the share price is ₹740.55, and it has been rising for 25 weeks. Its P/E of 148.7× is higher than 97% of its own last 5 years (as of 4 November 2026). ### Where is Krishna Institute of Medical Sciences in its business cycle? Krishna Institute of Medical Sciences Ltd's FY26 operating margin was 21.0%, against a 11-year range of 9.0% to 32.0%: the middle of its own range, neither a peak nor a low. The latest quarter was 19.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 4 November 2026). ### What could break the Krishna Institute of Medical Sciences story? The main question: the share price moved +1.7% in a year while yearly earnings per share moved −37.3%. The difference came from the market paying a higher multiple. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 4 November 2026). ### Is Krishna Institute of Medical Sciences a stock worth studying right now? What the numbers show: Krishna Institute of Medical Sciences Ltd's share price has risen faster than its earnings: +1.7% in a year, against −37.3% for earnings per share. The main open question: whether earnings grow into a price that has already moved. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 4 November 2026). ### Is there a Krishna Institute of Medical Sciences share price forecast for 2026? What management itself guided: Current hospitals prioritized for stabilization over the next two quarters; Nashik commissioning planned in three to four months, Electronic City break-even within one to two quarters, and Bangalore full-year operating profit neutrality. ### Where does this page get Krishna Institute of Medical Sciences' management information? From Krishna Institute of Medical Sciences' results calls, its filings and public records on governance, each dated on the page. Management’s plans are shown as plans, never as results. ## Lists

- Small & mid cap stocks: https://www.sectoralpha.in/small-cap-stocks-india

This is research, not advice. We’re not SEBI-registered.